Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | POLQ | O75417 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820021 | 0.80 | ALDH1A1 (0.48) | POLQALDH1A1KMT2AMEN1POLB | |
| SCHEMBL1819056 | 0.79 | KMT2A (0.51) | DRD4POLQALDH1A1KMT2AMEN1 | |
| SCHEMBL1818937 | 0.77 | NOTUM (0.51) | POLQALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL1819075 | 0.75 | KMT2A (0.54) | POLQALDH1A1KMT2AMEN1POLB | |
| SCHEMBL11675144 | 0.73 | KMT2A (0.53) | POLQALDH1A1KMT2AMEN1POLB | |
| SCHEMBL23558023 | 0.72 | ATM (0.58) | ALDH1A1KMT2APOLBKDM4E | |
| SCHEMBL1820114 | 0.72 | KMT2A (0.51) | POLQALDH1A1KMT2AMEN1POLB | |
| SCHEMBL1507876 | 0.71 | ALDH1A1 (0.64) | DRD4POLQALDH1A1KMT2AMEN1 | |
| SCHEMBL9152678 | 0.71 | HTR3E (0.48) | POLQALDH1A1KMT2A | |
| SCHEMBL1760632 | 0.70 | KMT2A (0.58) | POLQALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947712-B2 | Antiarthritic agents; asthma; chronic obstructive pulminary diosrders; atherosclerosis; vision defects; hepatitis; central nervous system disorders; cardiovascular disorders; wound healing agents; restenosis; cirrhosis; multiple sclerosis; glomerulonephritis; graft versus host disease; antidiabetic agent | WYETH LLC (US) | 2011-05-24 | — | — | US | disclosed |